Press Release
Akebia Therapeutics Announces Proposed Public Offering of Common Stock
Akebia intends to use the net proceeds from the offering for the continued clinical development and optimization of the vadadustat program, including pre-commercial planning activities, and the remainder for working capital, business development and other general corporate purposes.
The shares of common stock described above are being offered by Akebia
pursuant to an automatically effective shelf registration statement on
Form S-3 (File No. 333-223585) previously filed with the
This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in the offering, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
About
Forward-Looking Statements
Certain statements contained in this press release, including those
relating to the terms of the offering and expected use of proceeds from
the sale of common stock, are forward-looking statements that involve a
number of risks and uncertainties that could cause actual results to
differ materially from those in the forward-looking statements. These
risks and uncertainties include, but are not limited to, risks and
uncertainties associated with the consummation of the proposed offering
and general economic conditions and other risks identified from time to
time in the reports we file with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20180322006247/en/
Source:
Akebia Therapeutics Contact:
John Garabo, 617-844-6130
Director,
Corporate Communications
jgarabo@akebia.com
Akebia Therapeutics, Inc.
245 First Street, Suite 1400
Cambridge, MA 02142
+1 617.871.2098 phone
+1 617.871.2099 fax